secwatch.observer — SEC 8-K summary
======================================

Issuer:     SPRUCE BIOSCIENCES, INC. (SPRB)
CIK:        0001683553
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-007038
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 2.03, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spruce Biosciences secures up to $50M loan facility from Avenue Capital; initial $15M funded
--------------------------------------------------------------------------------

- Loan facility up to $50M from Avenue Capital; initial $15M tranche funded on Jan 9, 2026.
- Additional $35M available in 3 tranches tied to regulatory/commercial milestones for TA-ERT (MPS IIIB).
- Preliminary unaudited cash & equivalents ~$48.9M as of Dec 31, 2025; combined with initial tranche extends runway into 2027.
- Loan matures July 1, 2029; interest rate greater of prime+5.25% or 12.25%; no financial covenants.
- Warrant issued for up to $3.2M in common stock; exercise price lesser of $84.75 or next equity round price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526007038/0001193125-26-007038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1683553/000119312526007038/sprb-20260107.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer